GNI Group Bilan de santé

Santé financière contrôle des critères 4/6

GNI Group possède un total de capitaux propres de ¥36.0B et une dette totale de ¥6.3B, ce qui porte son ratio d'endettement à 17.5%. Son actif total et son passif total sont ¥62.7B et de ¥26.8B. L'EBIT de GNI Group est ¥8.6B ce qui fait que son ratio de couverture des intérêts 13.5. Elle dispose de liquidités et de placements à court terme de ¥14.0B.

Informations clés

17.5%

Ratio d'endettement

JP¥6.30b

Dette

Ratio de couverture des intérêts	13.5x
Argent liquide	JP¥14.05b
Fonds propres	JP¥35.98b
Total du passif	JP¥26.77b
Total des actifs	JP¥62.75b

Mises à jour récentes de la santé financière

Is GNI Group (TSE:2160) Using Too Much Debt?

Apr 12

Recent updates

After Leaping 48% GNI Group Ltd. (TSE:2160) Shares Are Not Flying Under The Radar

Sep 20

GNI Group's (TSE:2160) Shareholders Should Assess Earnings With Caution

Aug 27

GNI Group Ltd. (TSE:2160) Stock's 37% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 06

Investors Continue Waiting On Sidelines For GNI Group Ltd. (TSE:2160)

Jun 20

Is GNI Group (TSE:2160) Using Too Much Debt?

Apr 12

News Flash: Analysts Just Made An Incredible Upgrade To Their GNI Group Ltd. (TSE:2160) Forecasts

Mar 19

Further Upside For GNI Group Ltd. (TSE:2160) Shares Could Introduce Price Risks After 40% Bounce

Feb 28

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 2160 ( ¥27.3B ) dépassent ses passifs à court terme ( ¥10.2B ).

Passif à long terme: Les actifs à court terme de 2160 ( ¥27.3B ) dépassent ses passifs à long terme ( ¥16.6B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 2160 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 2160 est passé de 14.5% à 17.5% au cours des 5 dernières années.

Couverture de la dette: La dette de 2160 n'est pas bien couverte par le flux de trésorerie opérationnel ( 0.8% ).

Couverture des intérêts: Les paiements d'intérêts de 2160 sur sa dette sont bien couverts par l'EBIT ( 13.5 x couverture).

GNI Group Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Is GNI Group (TSE:2160) Using Too Much Debt?

Recent updates

Third quarter 2024 earnings released: EPS: JP¥19.48 (vs JP¥11.67 in 3Q 2023)

GNI Group Ltd. to Report Q3, 2024 Results on Nov 14, 2024

After Leaping 48% GNI Group Ltd. (TSE:2160) Shares Are Not Flying Under The Radar

Investor sentiment improves as stock rises 19%

GNI Group's (TSE:2160) Shareholders Should Assess Earnings With Caution

Investor sentiment improves as stock rises 21%

Second quarter 2024 earnings released: EPS: JP¥3.31 (vs JP¥34.98 in 2Q 2023)

Investor sentiment deteriorates as stock falls 24%

GNI Group Ltd. (TSE:2160) Stock's 37% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

Investors Continue Waiting On Sidelines For GNI Group Ltd. (TSE:2160)

GNI Group Ltd. to Report Q2, 2024 Results on Aug 14, 2024

High number of new directors

Is GNI Group (TSE:2160) Using Too Much Debt?

GNI Group Ltd. to Report Q1, 2024 Results on May 15, 2024

News Flash: Analysts Just Made An Incredible Upgrade To Their GNI Group Ltd. (TSE:2160) Forecasts

Consensus revenue estimates increase by 38%

Further Upside For GNI Group Ltd. (TSE:2160) Shares Could Introduce Price Risks After 40% Bounce

Investor sentiment improves as stock rises 43%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

GNI Group Ltd., Annual General Meeting, Mar 28, 2024

New minor risk - Shareholder dilution

GNI Group Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2023 earnings released: EPS: JP¥11.67 (vs JP¥8.40 in 3Q 2022)

GNI Group Ltd. Announces New Management Structure

Investor sentiment improves as stock rises 44%

New major risk - Earnings quality

Second quarter 2023 earnings released: EPS: JP¥34.96 (vs JP¥6.85 in 2Q 2022)

Consensus EPS estimates fall by 47%

Gni Group Ltd. Announces Notice of Executive Officer Appointment

New major risk - Share price stability

First quarter 2023 earnings released: JP¥0.042 loss per share (vs JP¥7.40 profit in 1Q 2022)

Beijing Continent Achieves Mid-Point Subject Enrollment for F351 Phase III Clinical Trial in China

Less than half of directors are independent

Full year 2022 earnings released: EPS: JP¥9.61 (vs JP¥22.72 in FY 2021)

GNI Group Ltd. to Report Fiscal Year 2022 Final Results on Mar 31, 2023

GNI Group Ltd., Annual General Meeting, Mar 30, 2023

Investor sentiment improved over the past week

GNI Group Ltd. Appoints of Kazuhiro Kawauchi as Chief Business Development Officer, Effective from January 1, 2023

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

GNI Group Ltd. to Report Fiscal Year 2022 Results on Feb 15, 2023

EP Mediate Co., Ltd. signed an agreement to acquire 60% stake in Micren Healthcare Co., Ltd.

Third quarter 2022 earnings released: EPS: JP¥8.42 (vs JP¥7.42 in 3Q 2021)

GNI Group Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings released: EPS: JP¥6.85 (vs JP¥10.76 in 2Q 2021)

GNI Group Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 2022

Consensus forecasts updated

Investor sentiment improved over the past week

Investor sentiment improved over the past week

GNI Group Ltd. Provides Earnings Guidance for the Year December 31, 2022

Price target decreased to JP¥2,100

GNI Group Ltd. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

GNI Group Ltd. Announces Board Changes

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

GNI Group Ltd. Provides Earnings Guidance for the Year Ending December 31, 2022

GNI Group Ltd., Annual General Meeting, Mar 25, 2022

GNI Group Ltd. Announces F351 Phase III Clinical Trial Roadmap in China

GNI Group Ltd. Announces F351 Phase III Clinical Trial Roadmap in China

Investor sentiment deteriorated over the past week

GNI Group Ltd. Announces First Dosing of F573 Phase I Clinical Trial in China

GNI Group Ltd. Announces First Patient Enrollment of F351 Phase III Clinical Trial in China

Third quarter 2021 earnings released: EPS JP¥7.44 (vs JP¥5.11 in 3Q 2020)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS JP¥28.96 (vs JP¥4.28 in FY 2019)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS JP¥25.05 (vs JP¥4.28 in FY 2019)

GNI Group Ltd. announced that it expects to receive ¥86.42546 million in funding from CVI Investments, Inc.

New 90-day high: JP¥2,179

GNI Group Ltd. announced that it has received ¥3.899411748 billion in funding

GNI Group Ltd. to Report Fiscal Year 2020 Results on Feb 12, 2021

New 90-day low: JP¥1,722